201 related articles for article (PubMed ID: 23582304)
21. Vpu-Mediated Counteraction of Tetherin Is a Major Determinant of HIV-1 Interferon Resistance.
Kmiec D; Iyer SS; Stürzel CM; Sauter D; Hahn BH; Kirchhoff F
mBio; 2016 Aug; 7(4):. PubMed ID: 27531907
[TBL] [Abstract][Full Text] [Related]
22. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
[TBL] [Abstract][Full Text] [Related]
23. Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens.
Lau D; Kwan W; Guatelli J
J Virol; 2011 Oct; 85(19):9834-46. PubMed ID: 21813615
[TBL] [Abstract][Full Text] [Related]
24. Filamin A Is Involved in HIV-1 Vpu-mediated Evasion of Host Restriction by Modulating Tetherin Expression.
Dotson D; Woodruff EA; Villalta F; Dong X
J Biol Chem; 2016 Feb; 291(8):4236-46. PubMed ID: 26742839
[TBL] [Abstract][Full Text] [Related]
25. Activities of transmitted/founder and chronic clade B HIV-1 Vpu and a C-terminal polymorphism specifically affecting virion release.
Jafari M; Guatelli J; Lewinski MK
J Virol; 2014 May; 88(9):5062-78. PubMed ID: 24574397
[TBL] [Abstract][Full Text] [Related]
26. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment.
Dubé M; Roy BB; Guiot-Guillain P; Binette J; Mercier J; Chiasson A; Cohen EA
PLoS Pathog; 2010 Apr; 6(4):e1000856. PubMed ID: 20386718
[TBL] [Abstract][Full Text] [Related]
27. Conserved residues within the HIV-1 Vpu transmembrane-proximal hinge region modulate BST2 binding and antagonism.
Lukhele S; Cohen ÉA
Retrovirology; 2017 Mar; 14(1):18. PubMed ID: 28288652
[TBL] [Abstract][Full Text] [Related]
28. Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses.
Lim ES; Malik HS; Emerman M
J Virol; 2010 Jul; 84(14):7124-34. PubMed ID: 20444900
[TBL] [Abstract][Full Text] [Related]
29. Ion channel activity of HIV-1 Vpu is dispensable for counteraction of CD317.
Bolduan S; Votteler J; Lodermeyer V; Greiner T; Koppensteiner H; Schindler M; Thiel G; Schubert U
Virology; 2011 Jul; 416(1-2):75-85. PubMed ID: 21601230
[TBL] [Abstract][Full Text] [Related]
30. Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network.
Dubé M; Roy BB; Guiot-Guillain P; Mercier J; Binette J; Leung G; Cohen EA
J Virol; 2009 May; 83(9):4574-90. PubMed ID: 19244337
[TBL] [Abstract][Full Text] [Related]
31. HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef.
Sauter D; Hué S; Petit SJ; Plantier JC; Towers GJ; Kirchhoff F; Gupta RK
Retrovirology; 2011 Dec; 8():103. PubMed ID: 22171785
[TBL] [Abstract][Full Text] [Related]
32. Some human immunodeficiency virus type 1 Vpu proteins are able to antagonize macaque BST-2 in vitro and in vivo: Vpu-negative simian-human immunodeficiency viruses are attenuated in vivo.
Shingai M; Yoshida T; Martin MA; Strebel K
J Virol; 2011 Oct; 85(19):9708-15. PubMed ID: 21775449
[TBL] [Abstract][Full Text] [Related]
33. The viral protein U (Vpu)-interacting host protein ATP6V0C down-regulates cell-surface expression of tetherin and thereby contributes to HIV-1 release.
Waheed AA; Swiderski M; Khan A; Gitzen A; Majadly A; Freed EO
J Biol Chem; 2020 May; 295(21):7327-7340. PubMed ID: 32291285
[TBL] [Abstract][Full Text] [Related]
34. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.
Iwabu Y; Fujita H; Kinomoto M; Kaneko K; Ishizaka Y; Tanaka Y; Sata T; Tokunaga K
J Biol Chem; 2009 Dec; 284(50):35060-72. PubMed ID: 19837671
[TBL] [Abstract][Full Text] [Related]
35. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.
Jia B; Serra-Moreno R; Neidermyer W; Rahmberg A; Mackey J; Fofana IB; Johnson WE; Westmoreland S; Evans DT
PLoS Pathog; 2009 May; 5(5):e1000429. PubMed ID: 19436700
[TBL] [Abstract][Full Text] [Related]
36. HIV-1 Vpu antagonizes BST-2 by interfering mainly with the trafficking of newly synthesized BST-2 to the cell surface.
Dubé M; Paquay C; Roy BB; Bego MG; Mercier J; Cohen EA
Traffic; 2011 Dec; 12(12):1714-29. PubMed ID: 21902775
[TBL] [Abstract][Full Text] [Related]
37. Transmembrane interactions of HIV-1 Vpu and tetherin.
Guo F; Liang C
Curr HIV Res; 2012 Jun; 10(4):292-7. PubMed ID: 22524177
[TBL] [Abstract][Full Text] [Related]
38. Analysis of the human immunodeficiency virus type 1 M group Vpu domains involved in antagonizing tetherin.
Petit SJ; Blondeau C; Towers GJ
J Gen Virol; 2011 Dec; 92(Pt 12):2937-2948. PubMed ID: 21900423
[TBL] [Abstract][Full Text] [Related]
39. BST-2 mediated restriction of simian-human immunodeficiency virus.
Ruiz A; Lau D; Mitchell RS; Hill MS; Schmitt K; Guatelli JC; Stephens EB
Virology; 2010 Oct; 406(2):312-21. PubMed ID: 20708210
[TBL] [Abstract][Full Text] [Related]
40. Modulation of HIV-1-host interaction: role of the Vpu accessory protein.
Dubé M; Bego MG; Paquay C; Cohen ÉA
Retrovirology; 2010 Dec; 7():114. PubMed ID: 21176220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
